{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:10:43Z","timestamp":1790701843213,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109309","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:31:06Z","timestamp":1770507066000},"page":"109309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6223-3454","authenticated-orcid":false,"given":"Ryosuke","family":"Tsugitomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-6399","authenticated-orcid":false,"given":"Go","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-220X","authenticated-orcid":false,"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-5233","authenticated-orcid":false,"given":"Hironori","family":"Ashinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4692","authenticated-orcid":false,"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-0618","authenticated-orcid":false,"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-0155","authenticated-orcid":false,"given":"Hideki","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0513-2860","authenticated-orcid":false,"given":"Yosuke","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-7202","authenticated-orcid":false,"given":"Yoshihito","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8071-5299","authenticated-orcid":false,"given":"Sousuke","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1500-5215","authenticated-orcid":false,"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5090","authenticated-orcid":false,"given":"Taro","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-1152","authenticated-orcid":false,"given":"Hiromi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0858-8107","authenticated-orcid":false,"given":"Hiroaki","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-8915","authenticated-orcid":false,"given":"Takehiro","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-3988","authenticated-orcid":false,"given":"Megumi","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-2260","authenticated-orcid":false,"given":"Hayato","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-8789","authenticated-orcid":false,"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5333-4969","authenticated-orcid":false,"given":"Masashi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2026.109309_b0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/hyz203","article-title":"National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015","volume":"50","author":"Koizumi","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"102645","key":"10.1016\/j.lungcan.2026.109309_b0010","article-title":"The contribution of rural\/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000-2020 database","volume":"92","author":"Cascone","year":"2024","journal-title":"Cancer Epidemiol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109309_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109309_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"Supplement 5","key":"10.1016\/j.lungcan.2026.109309_b0025","first-page":"v40","article-title":"on behalf of the ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"ESMO Updated Clinical Practice Guidelines"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109309_b0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1471-2407-14-349","article-title":"Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center","volume":"14","author":"Okuma","year":"2014","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109309_b0035","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109309_b0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109309_b0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109309_b0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109309_b0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Ann. Oncol."},{"issue":"C","key":"10.1016\/j.lungcan.2026.109309_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat Rev."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109309_b0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109309_b0070","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10126","key":"10.1016\/j.lungcan.2026.109309_b0075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109309_b0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"107557","key":"10.1016\/j.lungcan.2026.109309_b0085","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho","year":"2024","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109309_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105301","article-title":"Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings","volume":"10","author":"Takagi","year":"2025","journal-title":"ESMO Open"},{"issue":"7 Suppl 3","key":"10.1016\/j.lungcan.2026.109309_b0095","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109309_b0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109309_b0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109309_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70047","article-title":"Real-world efficacy and safety of lenvatinib in advanced or recurrent thymic carcinoma: a multicenter retrospective study in Japan","volume":"16","author":"Miyamoto","year":"2025","journal-title":"Thorac Cancer."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109309_b0115","article-title":"S1701, a randomized phase 2 trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma","volume":"5","author":"Tsao","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109309_b0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/mco.2017.1265","article-title":"Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer","volume":"7","author":"Suyama","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109309_b0125","first-page":"311","article-title":"Poor tolerability of lenvatinib in elderly patients with advanced hepatocellular carcinoma after disease progression following first-line atezolizumab plus bevacizumab: a multicenter study","volume":"103","author":"Kato","year":"2025","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109309_b0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/10781552221077039","article-title":"Poor tolerability of lenvatinib in elderly patients \u226580 years old with hepatocellular carcinoma: a multicenter observational study","volume":"29","author":"Kinoshita","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.lungcan.2026.109309_b0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2016.03.012","article-title":"Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria","volume":"96","author":"Kim","year":"2016","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109309_b0140","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/cas.12826","article-title":"Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Kiyota","year":"2015","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109309_b0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J. Gastroenterol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:59Z","timestamp":1790700359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022600053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S016950022600053X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109309","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109309"}}